CARL
CARLSMED, INC.
Next earnings Aug 26, 2026 · consensus $-0.41 EPS, $18.4M rev
Last earnings -1.9% on 2026-05-05
$11.76
▲ +4.63%$11.76▲ 0.00%
over 1Y
L $0.00EODHDH $16.99
Earnings Dividend Split Congress buy Congress sellGrouped by date · hover a pin to expand
Today+4.6%
1W+19.5%
1M+0.3%
3M+21.7%
YTD+1.1%
1Y—
Hold
Conviction
Horizon
Medium (3–12mo)
Street · 11 analysts
Buy
Revenue grew 85.9% YoY; but unprofitable (net margin -58.7%).
Revenue (FY2025) $50.5M · FY2025
CARLSMED, INC. shows $50.5M in FY2025 revenue (+85.9% YoY), a -58.7% net margin, and -30.0% ROE.
Financials · annual, by fiscal year
| Line item | FY24 | FY25 |
|---|---|---|
| Revenue | $27.2M | $50.5M |
| Gross profit | $20.0M | $38.0M |
| Operating income | -$24.1M | -$30.6M |
| Net income | -$24.3M | -$29.6M |
| Diluted EPS | -$6.11 | -$2.12 |
| Net margin | -89.3% | -58.7% |
Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.
Key statistics
Valuation
Enterprise value$244M
EV / EBITDA—
EV / Sales4.8
EV / FCF—
P / FCF—
PEG (trailing)—
Earnings yield-9.4%
FCF yield-9.4%
Quality & risk
ROIC (est.)-21.1%
Free cash flow-$29.6M
Total debt$15.3M
Net cash$70.4M
Altman Z-Score5.60 safe
Piotroski F-Score5/8
Capital returns
Buyback yield—
Dividend yield (est.)—
Shareholder yield—
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
Disclosure timeline
SEC · 8-Ks + reportsRoutine disclosure cadence — no material red flags in recent filings.
Recent filings
all on EDGAR ↗4Period ending 2026-06-032026-06-22open ↗4Period ending 2026-06-032026-06-22open ↗4Period ending 2026-06-032026-06-22open ↗4Period ending 2026-06-032026-06-22open ↗8-KPeriod ending 2026-06-032026-06-03open ↗10-QPeriod ending 2026-03-312026-05-05open ↗8-KPeriod ending 2026-05-052026-05-05open ↗ARSPeriod ending 2025-12-312026-04-22open ↗DEFA14AFiling2026-04-22open ↗DEF 14APeriod ending 2026-06-032026-04-22open ↗4Period ending 2026-03-022026-03-04open ↗144Filing2026-03-02open ↗
Frequently asked
- Is CARLSMED, INC. (CARL) a buy?
- CARL currently carries a Hold rating with 2/5 conviction, derived from its latest SEC filings. Revenue grew 85.9% YoY; but unprofitable (net margin -58.7%).
- What is CARLSMED, INC.'s quality score?
- CARL scores 47.745098039215684/100 (grade D) on a SEC-grounded quality model spanning value, growth, profitability, financial health and momentum.
Sources: SEC EDGAR (CIK 0001794546, latest 10-Q filed 2026-05-05) · EODHD · as of 6/26/2026, 8:03:15 PM.
Research and education only — not financial advice. EDGAR is not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities EDGAR rates; see Disclosures. Past performance does not guarantee future results. Do your own research.